Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc‐fused interleukin‐1 receptor antagonist, in healthy subjects: A first‐in‐human study

Aims We performed a first‐in‐human study with HL2351, a novel hybrid Fc‐fused interleukin (IL)‐1 receptor antagonist, to evaluate its tolerability, pharmacokinetics and pharmacodynamics (PD) after a single subcutaneous (SC) administration in healthy subjects. Methods A randomized, double‐blind, plac...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of clinical pharmacology 2020-02, Vol.86 (2), p.372-379
Hauptverfasser:	Oh, Jaeseong, Huh, Ki Young, Cho, Young‐Gyu, Cha, Ji‐Eun, Kim, Se‐Jin, Yoon, Seo Hyun, Park, Sung Sup, Yoon, Hyunyee, Lee, Jieon, Lee, Howard
Format:	Artikel
Sprache:	eng
Schlagworte:	biopharmaceutics monoclonal antibodies Original pharmacodynamics pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!